The in vitro effect on T cell function of soluble IL-2Rα from advanced ovarian cancer ascites

Steven A. Elg, Robert B. Hill, Leslie Heldman, Sundaram Ramakrishnan

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Activated T cells not only secrete interleukin-2 (II-2) and express cell surface interleukin 2 receptor α (IL-2Rα), but also shed IL-2Rα. This soluble receptor is a truncated form of the membrane-bound p55 receptor with a similar binding affinity. It has been proposed that soluble IL-2Rα (sIL- 2Rα) could negatively modulate local immune response. High levels of sIL- 2Rα have been found in the serum and ascites of ovarian cancer patients. The purpose of this investigation is to determine the amount of in vitro T cell inhibition seen in ovarian cancer ascites that is attributable to high levels of sIL-2Rα. Purified sIL-2Rα at levels up to 100,000 pg/ml was placed in lymphocyte proliferation assays. Soluble IL-2Rα was removed from the ascites of three patients with advanced ovarian cancer. Lymphocyte proliferation assays utilizing phytohemaglutin (PHA) stimulation were carried out with this ascites. Untreated ascites from each patient served as control. Addition of purified sIL-2Rα to lymphocyte proliferation assays failed to demonstrate significant lymphocyte suppression. Addition of ascites to the lymphocyte assays resulted in up to an 80% decrease in lymphocyte proliferation. Neutralization of ascites sIL-2Rα as well as removal of sIL-2Rα via a protein G column failed to reverse any of the observed lymphocyte suppression. We conclude that although sIL2Rα is elevated in ascites of patients with ovarian cancer, it does not account for the profound ascites- induced T cell suppression observed in vitro.

Original languageEnglish (US)
Pages (from-to)133-137
Number of pages5
JournalGynecologic Oncology
Volume66
Issue number1
DOIs
StatePublished - Jan 1 1997
Externally publishedYes

Fingerprint

Interleukin-2 Receptors
Ascites
Ovarian Neoplasms
T-Lymphocytes
Lymphocytes
In Vitro Techniques
Interleukin-2
Membranes

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

Cite this

The in vitro effect on T cell function of soluble IL-2Rα from advanced ovarian cancer ascites. / Elg, Steven A.; Hill, Robert B.; Heldman, Leslie; Ramakrishnan, Sundaram.

In: Gynecologic Oncology, Vol. 66, No. 1, 01.01.1997, p. 133-137.

Research output: Contribution to journalArticle

Elg, Steven A. ; Hill, Robert B. ; Heldman, Leslie ; Ramakrishnan, Sundaram. / The in vitro effect on T cell function of soluble IL-2Rα from advanced ovarian cancer ascites. In: Gynecologic Oncology. 1997 ; Vol. 66, No. 1. pp. 133-137.
@article{cbac76c5bdfb4be3b5bce6dee353957b,
title = "The in vitro effect on T cell function of soluble IL-2Rα from advanced ovarian cancer ascites",
abstract = "Activated T cells not only secrete interleukin-2 (II-2) and express cell surface interleukin 2 receptor α (IL-2Rα), but also shed IL-2Rα. This soluble receptor is a truncated form of the membrane-bound p55 receptor with a similar binding affinity. It has been proposed that soluble IL-2Rα (sIL- 2Rα) could negatively modulate local immune response. High levels of sIL- 2Rα have been found in the serum and ascites of ovarian cancer patients. The purpose of this investigation is to determine the amount of in vitro T cell inhibition seen in ovarian cancer ascites that is attributable to high levels of sIL-2Rα. Purified sIL-2Rα at levels up to 100,000 pg/ml was placed in lymphocyte proliferation assays. Soluble IL-2Rα was removed from the ascites of three patients with advanced ovarian cancer. Lymphocyte proliferation assays utilizing phytohemaglutin (PHA) stimulation were carried out with this ascites. Untreated ascites from each patient served as control. Addition of purified sIL-2Rα to lymphocyte proliferation assays failed to demonstrate significant lymphocyte suppression. Addition of ascites to the lymphocyte assays resulted in up to an 80{\%} decrease in lymphocyte proliferation. Neutralization of ascites sIL-2Rα as well as removal of sIL-2Rα via a protein G column failed to reverse any of the observed lymphocyte suppression. We conclude that although sIL2Rα is elevated in ascites of patients with ovarian cancer, it does not account for the profound ascites- induced T cell suppression observed in vitro.",
author = "Elg, {Steven A.} and Hill, {Robert B.} and Leslie Heldman and Sundaram Ramakrishnan",
year = "1997",
month = "1",
day = "1",
doi = "10.1006/gyno.1997.4741",
language = "English (US)",
volume = "66",
pages = "133--137",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - The in vitro effect on T cell function of soluble IL-2Rα from advanced ovarian cancer ascites

AU - Elg, Steven A.

AU - Hill, Robert B.

AU - Heldman, Leslie

AU - Ramakrishnan, Sundaram

PY - 1997/1/1

Y1 - 1997/1/1

N2 - Activated T cells not only secrete interleukin-2 (II-2) and express cell surface interleukin 2 receptor α (IL-2Rα), but also shed IL-2Rα. This soluble receptor is a truncated form of the membrane-bound p55 receptor with a similar binding affinity. It has been proposed that soluble IL-2Rα (sIL- 2Rα) could negatively modulate local immune response. High levels of sIL- 2Rα have been found in the serum and ascites of ovarian cancer patients. The purpose of this investigation is to determine the amount of in vitro T cell inhibition seen in ovarian cancer ascites that is attributable to high levels of sIL-2Rα. Purified sIL-2Rα at levels up to 100,000 pg/ml was placed in lymphocyte proliferation assays. Soluble IL-2Rα was removed from the ascites of three patients with advanced ovarian cancer. Lymphocyte proliferation assays utilizing phytohemaglutin (PHA) stimulation were carried out with this ascites. Untreated ascites from each patient served as control. Addition of purified sIL-2Rα to lymphocyte proliferation assays failed to demonstrate significant lymphocyte suppression. Addition of ascites to the lymphocyte assays resulted in up to an 80% decrease in lymphocyte proliferation. Neutralization of ascites sIL-2Rα as well as removal of sIL-2Rα via a protein G column failed to reverse any of the observed lymphocyte suppression. We conclude that although sIL2Rα is elevated in ascites of patients with ovarian cancer, it does not account for the profound ascites- induced T cell suppression observed in vitro.

AB - Activated T cells not only secrete interleukin-2 (II-2) and express cell surface interleukin 2 receptor α (IL-2Rα), but also shed IL-2Rα. This soluble receptor is a truncated form of the membrane-bound p55 receptor with a similar binding affinity. It has been proposed that soluble IL-2Rα (sIL- 2Rα) could negatively modulate local immune response. High levels of sIL- 2Rα have been found in the serum and ascites of ovarian cancer patients. The purpose of this investigation is to determine the amount of in vitro T cell inhibition seen in ovarian cancer ascites that is attributable to high levels of sIL-2Rα. Purified sIL-2Rα at levels up to 100,000 pg/ml was placed in lymphocyte proliferation assays. Soluble IL-2Rα was removed from the ascites of three patients with advanced ovarian cancer. Lymphocyte proliferation assays utilizing phytohemaglutin (PHA) stimulation were carried out with this ascites. Untreated ascites from each patient served as control. Addition of purified sIL-2Rα to lymphocyte proliferation assays failed to demonstrate significant lymphocyte suppression. Addition of ascites to the lymphocyte assays resulted in up to an 80% decrease in lymphocyte proliferation. Neutralization of ascites sIL-2Rα as well as removal of sIL-2Rα via a protein G column failed to reverse any of the observed lymphocyte suppression. We conclude that although sIL2Rα is elevated in ascites of patients with ovarian cancer, it does not account for the profound ascites- induced T cell suppression observed in vitro.

UR - http://www.scopus.com/inward/record.url?scp=0031194483&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031194483&partnerID=8YFLogxK

U2 - 10.1006/gyno.1997.4741

DO - 10.1006/gyno.1997.4741

M3 - Article

C2 - 9234933

AN - SCOPUS:0031194483

VL - 66

SP - 133

EP - 137

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 1

ER -